36720900|t|PRMT5 is a therapeutic target in choroidal neovascularization.
36720900|a|Ocular neovascular diseases including neovascular age-related macular degeneration (nvAMD) are widespread causes of blindness. Patients' non-responsiveness to currently used biologics that target vascular endothelial growth factor (VEGF) poses an unmet need for novel therapies. Here, we identify protein arginine methyltransferase 5 (PRMT5) as a novel therapeutic target for nvAMD. PRMT5 is a well-known epigenetic enzyme. We previously showed that PRMT5 methylates and activates a proangiogenic and proinflammatory transcription factor, the nuclear factor kappa B (NF-kappaB), which has a master role in tumor progression, notably in pancreatic ductal adenocarcinoma and colorectal cancer. We identified a potent and specific small molecule inhibitor of PRMT5, PR5-LL-CM01, that dampens the methylation and activation of NF-kappaB. Here for the first time, we assessed the antiangiogenic activity of PR5-LL-CM01 in ocular cells. Immunostaining of human nvAMD sections revealed that PRMT5 is highly expressed in the retinal pigment epithelium (RPE)/choroid where neovascularization occurs, while mouse eyes with laser induced choroidal neovascularization (L-CNV) showed PRMT5 is overexpressed in the retinal ganglion cell layer and in the RPE/choroid. Importantly, inhibition of PRMT5 by PR5-LL-CM01 or shRNA knockdown of PRMT5 in human retinal endothelial cells (HRECs) and induced pluripotent stem cell (iPSC)-derived choroidal endothelial cells (iCEC2) reduced NF-kappaB activity and the expression of its target genes, such as tumor necrosis factor alpha (TNF-alpha) and VEGF-A. In addition to inhibiting angiogenic properties of proliferation and tube formation, PR5-LL-CM01 blocked cell cycle progression at G1/S-phase in a dose-dependent manner in these cells. Thus, we provide the first evidence that inhibition of PRMT5 impedes angiogenesis in ocular endothelial cells, suggesting PRMT5 as a potential therapeutic target to ameliorate ocular neovascularization.
36720900	0	5	PRMT5	Gene	10419
36720900	33	61	choroidal neovascularization	Disease	MESH:D020256
36720900	63	90	Ocular neovascular diseases	Disease	MESH:D016510
36720900	101	145	neovascular age-related macular degeneration	Disease	MESH:D008268
36720900	147	152	nvAMD	Disease	MESH:D008268
36720900	179	188	blindness	Disease	MESH:D001766
36720900	190	198	Patients	Species	9606
36720900	259	293	vascular endothelial growth factor	Gene	7422
36720900	295	299	VEGF	Gene	7422
36720900	360	396	protein arginine methyltransferase 5	Gene	10419
36720900	398	403	PRMT5	Gene	10419
36720900	439	444	nvAMD	Disease	MESH:D008268
36720900	446	451	PRMT5	Gene	10419
36720900	513	518	PRMT5	Gene	10419
36720900	564	579	proinflammatory	Disease	
36720900	606	628	nuclear factor kappa B	Gene	4790
36720900	630	639	NF-kappaB	Gene	4790
36720900	669	674	tumor	Disease	MESH:D009369
36720900	699	731	pancreatic ductal adenocarcinoma	Disease	MESH:D021441
36720900	736	753	colorectal cancer	Disease	MESH:D015179
36720900	819	824	PRMT5	Gene	10419
36720900	826	837	PR5-LL-CM01	Chemical	MESH:C000627006
36720900	886	896	NF-kappaB.	Gene	4790
36720900	965	976	PR5-LL-CM01	Chemical	MESH:C000627006
36720900	1012	1017	human	Species	9606
36720900	1018	1023	nvAMD	Disease	MESH:D008268
36720900	1047	1052	PRMT5	Gene	10419
36720900	1080	1087	retinal	Disease	MESH:D012173
36720900	1108	1111	RPE	CellLine	CVCL:IQ82
36720900	1127	1145	neovascularization	Disease	MESH:D016510
36720900	1160	1165	mouse	Species	10090
36720900	1176	1181	laser	Disease	
36720900	1190	1218	choroidal neovascularization	Disease	MESH:D020256
36720900	1220	1225	L-CNV	Disease	MESH:D020256
36720900	1234	1239	PRMT5	Gene	27374
36720900	1264	1271	retinal	Disease	MESH:D012173
36720900	1303	1306	RPE	CellLine	CVCL:IQ82
36720900	1343	1348	PRMT5	Gene	10419
36720900	1352	1363	PR5-LL-CM01	Chemical	MESH:C000627006
36720900	1386	1391	PRMT5	Gene	10419
36720900	1395	1400	human	Species	9606
36720900	1401	1408	retinal	Disease	MESH:D012173
36720900	1528	1537	NF-kappaB	Gene	4790
36720900	1595	1622	tumor necrosis factor alpha	Gene	7124
36720900	1624	1633	TNF-alpha	Gene	7124
36720900	1639	1646	VEGF-A.	Gene	7422
36720900	1732	1743	PR5-LL-CM01	Chemical	MESH:C000627006
36720900	1887	1892	PRMT5	Gene	10419
36720900	1954	1959	PRMT5	Gene	10419
36720900	2015	2033	neovascularization	Disease	MESH:D016510
36720900	Negative_Correlation	MESH:C000627006	4790
36720900	Association	MESH:D016510	10419
36720900	Positive_Correlation	MESH:D020256	27374
36720900	Association	MESH:D012173	10419
36720900	Association	MESH:D008268	10419
36720900	Association	MESH:D021441	10419
36720900	Association	MESH:D020256	10419
36720900	Negative_Correlation	10419	7422
36720900	Association	MESH:D009369	10419
36720900	Association	MESH:D015179	4790
36720900	Association	MESH:D009369	4790
36720900	Positive_Correlation	MESH:D012173	27374
36720900	Negative_Correlation	MESH:C000627006	7124
36720900	Association	MESH:D015179	10419
36720900	Positive_Correlation	10419	7124
36720900	Negative_Correlation	MESH:C000627006	7422
36720900	Negative_Correlation	MESH:C000627006	10419
36720900	Positive_Correlation	10419	4790

